We look at some of the key biotech developments, companies, and clinical data to watch at AHA Scientific Sessions 2026.

While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative ...

ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates ...

Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs.

In an interview with Labiotech, Jacobs discussed the decisions behind Novavax’s transformation, the economics of its new ...

The companies Summit Therapeutics, Dren Bio, and Lycia Therapeutics bagged the biggest biotech funding rounds overall in October 2026.

Join leading experts to explore practical strategies for designing and delivering rare disease clinical trials in Europe.

Spain’s biotech ecosystem is no longer short of companies. The number of biotech firms reached 1,119 in 2025, up 10.4% in a year, while investment hit a record €408 million ($456,6 million). Investors ...

The priciest merger and acquisition (M&A) last month was Shionogi’s $2 billion buyout of IntraBio, a Texas-based company focused on treating rare and neurodegenerative diseases. The American biotech ...

GLP-1 is a hormone that is produced in the small intestine. The hormone binds to its receptor, which is expressed in various cells including in the pancreas, kidneys, heart, and skin. This hormone ...

People with polyendocrine metabolic ovarian syndrome (PMOS) are affected by hormone imbalances, impacting everything from mood to fertility. The cause of the condition is unknown, but the recent name ...

Vision loss remains one of the leading causes of disability worldwide, with millions affected by inherited retinal diseases, age-related macular degeneration, and diabetic eye disease. While existing ...